Spinraza scoops Best Biotechnology Product award

Biogen and Ionis receive 2017 Prix Galien USA Award for extraordinary achievement in scientific innovation.

“We are humbled to be recognized by the Galien Foundation with Ionis for Spinraza, the first and only therapy to treat the devastating condition of spinal muscular atrophy (SMA),” said Michel Vounatsos, chief executive officer at Biogen. “Spinraza’s profound clinical impact is certainly the most rewarding outcome for all of us involved, and I want to thank our Biogen colleagues around the world for their passion and commitment to making a difference in this area of medical need.”

The FDA approved Spinraza on 23 December 2016 under priority review for the treatment of SMA in pediatric and adult patients. SMA is a rare disease and leading genetic cause of death in infants marked by progressive, debilitating muscle weakness taking away a person’s ability to walk, eat and ultimately breathe. Spinraza is an approved therapy for the treatment of SMA.

Spinraza is the first approved medicine for the treatment of SMA and is currently approved in the US, the European Union, Brazil, Japan, Switzerland and Canada. Biogen has submitted regulatory filings in additional countries and plans to initiate additional filings in other countries.